EXAMPLE ROYALTY REPORT Sample Clauses

EXAMPLE ROYALTY REPORT. Required royalty report information includes: • XXX license reference number (L-XXX-200X/0) • Reporting period • Catalog number and units sold of each Licensed Product (domestic and foreign) • Gross Sales per catalog number per country • Total Gross Sales • Itemized deductions from Gross Sales • Total Net Sales • Earned Royalty Rate and associated calculations • Gross Earned Royalty • Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made • Net Earned Royalty due Example Catalog Number Product Name Country Units Sold Gross Sales (US$) 1 A US 250 62,500 1 A UK 32 16,500 1 A France 25 15,625 2 B US 0 0 3 C US 57 57,125 4 D US 12 1,500 Total Gross Sales 153,250 Less Deductions: Freight 3,000 Returns 7,000 Total Net Sales 143,250 Royalty Rate 8% Royalty Due 11,460 Less Creditable Payments 10,000 Net Royalty Due 1,460 A-293-2011 CONFIDENTIAL PHS Patent License Agreement—Exclusive Model 10-2005 (updated 4-2010) Page 26 of 28 [Final] [GlobeImmune, Inc] [December 7, 2011] SV\805701.4 GlobeImmune – Patent Lic. Agt. (Exclusive) – PHS (jointly owned ip) [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Sample 1Sample 2See All (5)
AutoNDA by SimpleDocs
EXAMPLE ROYALTY REPORT. Required royalty report information includes:  License reference number (L-XXX-200X/0)  Reporting periodCatalog number and units sold of each Licensed Product (domestic and foreign)  Gross Sales per catalog number per country  Total Gross SalesItemized deductions from Gross Sales  Total Net Sales  Earned Royalty Rate and associated calculations  Gross Earned Royalty  Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made  Net Earned Royalty due Example Catalog Number Product Name Country Units Sold Gross Sales (US$) 1 A US 250 62,500 1 A UK 32 16,500 1 A France 25 15,625 2 B US 0 0 3 C US 57 57,125 4 D US 12 1,500 Total Gross Sales 153,250 Less Deductions: Freight 3,000 Returns 7,000 Total Net Sales 143,250 Royalty Rate 8% Royalty Due 11,460 Less Creditable Payments 10,000 Net Royalty Due 1,460 APPENDIX C – ROYALTY PAYMENT OPTIONS New Payment Options Effective March 2018 The License Number MUST appear on payments, reports and correspondence. Credit and Debit Card Payments: Credit and debit card payments can be submitted for amounts up to $24,999. Submit your payment through the U.S. Treasury web site located at: xxxxx://xxx.xxx.xxx/public/form/start/28680443. Automated Clearing House (ACH) for payments through U.S. banks only The IC encourages its licensees to submit electronic funds transfer payments through the Automated Clearing House (ACH). Submit your ACH payment through the U.S. Treasury web site located at: xxxxx://xxx.xxx.xxx/public/form/start/28680443. Please note that the IC "only" accepts ACH payments through this U.S. Treasury web site.
Sample 1
EXAMPLE ROYALTY REPORT. Required royalty report information includes: • License reference number (L-XXX-200X/0) • Reporting period • Catalog number and units sold of each Licensed Product (domestic and foreign) • Gross Sales per catalog number per country • Total Gross Sales • Itemized deductions from Gross Sales • Total Net Sales • Earned Royalty Rate and associated calculations • Gross Earned Royalty • Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made • Net Earned Royalty due Example Catalog Number Product Name Country Units Sold Gross Sales (US$) 1 A US 250 62,500 1 A UK 32 16,500 1 A France 25 15,625 2 B US 0 0 3 C US 57 57,125 4 D US 12 1,500 Total Gross Sales 153,250 Less Deductions: Freight 3,000 Returns 7,000 Total Net Sales 143,250 Royalty Rate 8% Royalty Due 11,460 Less Creditable Payments 10,000 Net Royalty Due 1,460 A-429-2017 CONFIDENTIAL NIH Patent License Agreement-Exclusive [***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
Sample 1

Related to EXAMPLE ROYALTY REPORT

  • Royalty Report The term “Royalty Report” shall have the meaning ascribed to such term as provided in Section 5.4.

  • Royalty Reports After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY quarterly royalty reports on or before each February 28, May 31, August 31 and November 30 of each year. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar quarter and shall show:

  • PROGRESS AND ROYALTY REPORTS 8.1 For the period beginning [date] LICENSEE will submit to REGENTS a semi-annual progress report covering LICENSEE's activities related to the development and testing of all LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHOD and the obtaining of necessary governmental approvals, if any, for marketing in the United States. These progress reports will be made for all development activities until the first SALE occurs in the United States.

  • Royalty Statements The Licensees shall provide Shengqu with a statement within ten (10) Business Days of the end of each calendar month during the Term of this Agreement.

  • Reports and Royalty Payments Within [* * *] days after the beginning of each Contract Quarter during the Royalty Term, Celgene shall deliver to Acceleron a report setting forth for the previous Contract Quarter the following information on a Licensed Product-by-Licensed Product and country-by-country basis in the Territory: (a) the gross sales and Net Sales of Licensed Product, (b) the number of units sold by Celgene, its Affiliates or Sublicensees, (c) the basis for any adjustments to the royalty payable for the sale of each Licensed Product, and (d) the royalty due hereunder for the sales of each Licensed Product (the “Royalty Report”). The total royalty due for the sale of Licensed Products during such Contract Quarter shall be remitted at the time such report is made. No such reports or royalty shall be due for any Licensed Product before the First Commercial Sale of such Licensed Product.

  • Royalty Payment For all leased substances that are sold during a particular month, Lessee shall pay royalties to Lessor on or before the end of the next succeeding month. Royalty payments shall be accompanied by a verified statement, in a form approved by Lessor, stating the amount of leased substances sold, the gross proceeds accruing to Lessee, and any other information reasonably required by Lessor to verify production and disposition of the leased substances or leased substances products. Delinquent royalties may be subject to late fees and penalties in accordance with Lessor’s Rules.

  • Sublicense Revenue In the event Licensee or an Affiliate of Licensee sublicenses under Section 2.2, Licensee shall pay CareFusion **THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION.** of any Sublicense Revenues resulting from sublicense agreements executed by Licensee.

  • Royalty Reports and Accounting 10 6.1 "Royalty Reports; Records".................................... 10 6.2 "Payment Due Dates"........................................... 10 6.3 "Right to Audit Licensee"..................................... 11 6.4 "Right to Audit Cellegy"...................................... 11 6.5 "Overpayment or Underpayment of Burdened Cost"................ 11 6.6 "Disagreement with Auditor Findings".......................... 11

  • Earned Royalties Subject to of Article 7 hereof, Licensee shall pay to Licensor for the rights granted hereunder a sum equal to one and [*****] of the Net Invoice Value of Trademarked Products Sold by Licensee (the "Royalties"). The Royalties shall be remitted in accordance with Section 7.4 of this Agreement. 6.2

  • Know-How Royalty Notwithstanding the provisions of Section 5.4.1(a), in countries where the sale of Product by Merck or its Related Parties would not infringe a Valid Patent Claim, Merck shall pay royalty rates that shall be set at [***] of the applicable royalty rate determined according to Section 5.4.1(a). Such royalties shall be calculated after first calculating royalties under Section 5.4.1(a).

Time is Money Join Law Insider Premium to draft better contracts faster.